Comparison of Mortality and Amputation after Lower Extremity Bypass vs. Peripheral Vascular Intervention in Patients with Chronic Limb-Threatening Ischemia and Comorbid Chronic Kidney Disease
Cleman J, Sierra J, Romain G, Capuano B, Scierka L, Callegari S, Jacque F, Peri-Okonny P, Nagpal S, Smolderen K, Mena-Hurtado C. Comparison of Mortality and Amputation after Lower Extremity Bypass vs. Peripheral Vascular Intervention in Patients with Chronic Limb-Threatening Ischemia and Comorbid Chronic Kidney Disease. Journal Of Vascular Surgery 2024 PMID: 38608966, DOI: 10.1016/j.jvs.2024.04.016.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaAll-cause mortalityLower extremity bypassPeripheral vascular interventionsComorbid chronic kidney diseaseLimb-threatening ischemiaComparison of mortalityPreference-sensitive treatment decisionsCox proportional hazards modelsRisk of deathInteraction termsProportional hazards modelLower-extremity bypassChronic kidney diseaseFine-Gray modelMortality riskVascular interventionsAmputationHazards modelOutcome dataFine-GrayAssociated with worse outcomesHigh riskKidney diseasePropensity scoreVariability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions
Smolderen K, Romain G, Cleman J, Scierka L, Mena-Hurtado C. Variability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions. American Heart Journal 2024, 270: 75-85. PMID: 38307364, DOI: 10.1016/j.ahj.2024.01.008.Peer-Reviewed Original ResearchMedian odds ratioGuideline-directed medical therapy prescriptionGuideline-directed medical therapy ratesPeripheral vascular interventionsGuideline-directed medical therapyIntraclass correlationHealth system levelDecrease hospital readmissionsPatient-level factorsGuideline-directed medical therapy useAssociated with higher riskAngiotensin-converting enzyme inhibitor/angiotensin receptor blockerRisk of deathParametric survival modelsInhibitor/angiotensin receptor blockerProportion of riskHospital readmissionVascular Quality Initiative registryLong-term mortalityOdds ratioReadmission riskVascular interventionsLogistic regressionDose-response relationshipAmputation